Standard Biotools (LAB) Short-term Investments (2011 - 2026)

Standard Biotools (LAB) has 15 years of Short-term Investments data on file, last reported at $189.4 million in Q1 2026.

• On a quarterly basis, Short-term Investments rose 76.71% year-over-year to $189.4 million in Q1 2026; TTM through Mar 2026 was $189.4 million, a 76.71% increase from a year earlier, with the FY2025 full-year figure at $66.7 million, down 47.12% from the prior year.
• Short-term Investments for Q1 2026 stood at $189.4 million, up from $66.7 million in the prior quarter.
• Over the last five years, Short-term Investments for LAB reached as high as $189.4 million in Q1 2026 and fell as low as $40.9 million in Q1 2023.
• Historically, Short-term Investments has averaged $105.9 million across 5 years, with a median of $107.2 million in 2025.
• Across the five-year window, Short-term Investments sank 60.63% in 2023 and jumped 328.7% in 2024, its largest moves.
• Year by year, Short-term Investments stood at $84.5 million in 2022, then declined by 25.2% to $63.2 million in 2023, then soared by 99.63% to $126.1 million in 2024, then sank by 47.12% to $66.7 million in 2025, then jumped by 183.91% to $189.4 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $189.4 million in Q1 2026, $66.7 million in Q4 2025, and $65.5 million in Q3 2025.